Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) had its target price decreased by analysts at Guggenheim from $21.00 to $18.00 in a report released on Friday, FlyOnTheWall reports. Guggenheim’s price objective would suggest a potential upside of 8.17% from the company’s current price. Separately, HC Wainwright initiated coverage on shares of Calliditas Therapeutics […]
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $15.90, but opened at $16.64. Calliditas Therapeutics AB (publ) shares last traded at $16.86, with a volume of 19,324 shares changing hands. Analyst Ratings Changes A number of research firms have […]
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,900 shares, a drop of 24.0% from the July 15th total of 2,500 shares. Based on an average daily volume of 6,900 shares, the days-to-cover […]
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,900 shares, a drop of 24.0% from the July 15th total of 2,500 shares. Based on an average daily trading volume, of […]
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) saw a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 8,400 shares, an increase of 47.4% from the May 15th total of 5,700 shares. Based on an average daily volume of 11,000 shares, the short-interest ratio […]